Latest news with #CYC
CNA
9 hours ago
- Entertainment
- CNA
CNA938 Rewind - CYC – celebrating 90 years of heritage brand excellence
CNA938 Rewind Play In 'Made in SG', Melanie Oliveiro finds out about the history and staying power of heritage brand CYC, a clothing firm best known for its custom-made shirts and corporate wear. Mrs. Fong Loo Fern, Managing Director of CYC, will talk about how its story began in 1935 when it was founded by Shanghainese tailors Chiang Yick Ching, and his wife Mdm Foo Ah Neok. Celebrating CYC's 90th birthday during SG60, Fong will also discuss how Singapore's fashion and tailoring trends have evolved through the decades, and how CYC pioneered a combination of Western technology with Eastern craftsmanship in their designs. CNA938 Rewind - How Pangdemonium is exploring the ghost town Singapore, Michigan In 'Culture Club', Melanie Oliveiro speaks with the cast of the new Pangdemonium production 'Singapore, Michigan'. Actors Shrey Bhargava, Shu Yi Ching and Zane Haney discuss their roles in this play about two Singaporeans and an American on a quest to find the ghost town of Singapore, Michigan. What begins as a light-hearted adventure soon evolves into a journey of unexpected truths and existential reflection. Written by playwright Chong An Ong, the cast will also talk about the issues that resonated with them in this production. 30 mins CNA938 Rewind - CYC – celebrating 90 years of heritage brand excellence In 'Made in SG', Melanie Oliveiro finds out about the history and staying power of heritage brand CYC, a clothing firm best known for its custom-made shirts and corporate wear. Mrs. Fong Loo Fern, Managing Director of CYC, will talk about how its story began in 1935 when it was founded by Shanghainese tailors Chiang Yick Ching, and his wife Mdm Foo Ah Neok. Celebrating CYC's 90th birthday during SG60, Fong will also discuss how Singapore's fashion and tailoring trends have evolved through the decades, and how CYC pioneered a combination of Western technology with Eastern craftsmanship in their designs. 33 mins CNA938 Rewind - The Wellness Hour - Beat insomnia without pills Struggling to get a good night's sleep? Insomnia affects many Singaporeans and costs the economy billions every year. Hui Wong hears why pills aren't always the answer and how cognitive-behavioural therapy can help you reclaim restful nights—naturally and effectively with Julian Lim, Lead Psychologist and Co-Founder, Somnus Sleep Wellness 16 mins
Yahoo
19-03-2025
- Business
- Yahoo
Investors in Cyclopharm (ASX:CYC) have seen decent returns of 63% over the past five years
Cyclopharm Limited (ASX:CYC) shareholders might be concerned after seeing the share price drop 25% in the last month. But at least the stock is up over the last five years. However we are not very impressed because the share price is only up 58%, less than the market return of 119%. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. See our latest analysis for Cyclopharm Cyclopharm isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. For the last half decade, Cyclopharm can boast revenue growth at a rate of 11% per year. That's a pretty good long term growth rate. The annual gain of 10% over five years is better than nothing, but falls short of the market. Arguably, that means, the market (previously) expected stronger growth from the company. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). Take a more thorough look at Cyclopharm's financial health with this free report on its balance sheet. We'd be remiss not to mention the difference between Cyclopharm's total shareholder return (TSR) and its share price return. The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Dividends have been really beneficial for Cyclopharm shareholders, and that cash payout contributed to why its TSR of 63%, over the last 5 years, is better than the share price return. While the broader market gained around 4.9% in the last year, Cyclopharm shareholders lost 20%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 10%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Cyclopharm , and understanding them should be part of your investment process. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
